![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sunesis Pharmaceuticals Inc | NASDAQ:SNSS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.32 | 4.72 | 4.75 | 0 | 01:00:00 |
www.bedfordreport.com/2010-12-CTIC
www.bedfordreport.com/2010-12-SNSS
Recently the Obama administration pressed congress to revamp a research and development tax credit by increasing it by about 20 percent and making it permanent. The Pharmaceutical Research and Manufacturers of America, PhRMA, as well as the Advanced Medical Technology Association expressed support for the tax credit.
The Bedford Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us for free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
A recent survey from PricewaterhouseCoopers found that life sciences firms believe that industry-FDA relationships have improved since Obama took office. In fact, 80% of those surveyed said in the last two years the FDA has provided better guidance about its expectations.
In recent FDA-Biotech news, Cell Therapeutics announced this month that it has filed an appeal of the FDA's decision regarding the company's "pixantrone" drug for non-Hodgkin's lymphoma. Back in April the FDA recommended that cell Therapeutics conduct another trial of pixantrone "to demonstrate the safety and effectiveness of its product."
The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.bedfordreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
1 Year Sunesis Pharmaceuticals Chart |
1 Month Sunesis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions